Calico Pharmaceuticals Private Limited is a leading Indian pharmaceutical company committed to advancing global healthcare through cutting-edge research, quality manufacturing, and ethical practices.
Discover More
Established in 2005, Calico Pharmaceuticals Private Limited (CIN: U24230MH2005PTC157456) has grown into a renowned name in the Indian pharmaceutical industry, with a strong presence in over 30 countries. Our mission is to improve patient lives by developing and delivering high-quality, affordable medicines.
Headquartered in Mumbai, Maharashtra, we operate multiple WHO-GMP certified manufacturing facilities across India, equipped with advanced technology and adhering to stringent international standards. Our portfolio spans generics, biosimilars, and specialty drugs across therapeutic areas such as cardiology, oncology, neurology, and infectious diseases.
With a team of over 1,500 dedicated professionals, including 200+ scientists, we foster a culture of innovation and integrity. We hold numerous patents and have a robust pipeline of products under development. Our commitment to sustainability and corporate social responsibility is reflected in our community health initiatives and environmental practices.
Calico Pharmaceuticals is registered with the Indian Ministry of Corporate Affairs and holds all necessary licenses, including Drug Manufacturing License No. DL-5678-MH/2021 and GSTIN 27AAECC1574F1ZR. We comply with global regulatory frameworks like USFDA, EMA, and CDSCO.
We offer a comprehensive range of antihypertensives, anticoagulants, and lipid-lowering agents that meet global quality standards. Our products are trusted by healthcare professionals for efficacy and safety in managing cardiovascular diseases.
Our oncology portfolio includes chemotherapeutic agents, targeted therapies, and supportive care products. We focus on improving access to life-saving cancer treatments through affordable generics and innovative formulations.
We provide advanced therapies for neurological conditions such as epilepsy, migraine, and Parkinson's disease. Our R&D focuses on novel drug delivery systems to enhance patient compliance and outcomes.
Our range includes antibiotics, antivirals, antifungals, and antiparasitics crucial for combating infections. We prioritize antimicrobial stewardship and contribute to global efforts against drug resistance.
We offer end-to-end contract research services, from preclinical studies to clinical trials, leveraging our state-of-the-art laboratories and experienced team to accelerate drug development for partners worldwide.
Our WHO-GMP certified facilities provide flexible manufacturing solutions for tablets, capsules, injectables, and ointments. We ensure compliance with global regulations and deliver products on time.
With a robust supply chain network, we distribute pharmaceuticals to over 30 countries across Asia, Africa, Europe, and Latin America. Our logistics team ensures timely delivery and cold chain management.
At Calico Pharmaceuticals, innovation is at our core. Our R&D center in Pune is equipped with advanced instrumentation and staffed by a multidisciplinary team of scientists dedicated to discovering new therapeutic solutions.
We invest over 12% of our annual revenue into R&D, focusing on novel drug delivery systems, biosimilars, and complex generics. Our pipeline includes 15+ products in various stages of development, targeting unmet medical needs in oncology, diabetes, and rare diseases.
Our collaborations with academic institutions like the Indian Institute of Technology and international research organizations enhance our capabilities. We hold 25+ patents and have published numerous papers in reputed journals.
Our quality control laboratories adhere to ICH guidelines and are equipped with HPLC, GC-MS, and dissolution testers. We conduct rigorous stability studies to ensure product shelf-life and efficacy.
We are committed to ethical research practices and patient safety. All clinical trials are conducted in compliance with Good Clinical Practice (GCP) and approved by independent ethics committees.
June 15, 2023
Calico Pharmaceuticals inaugurated a new WHO-GMP certified facility in Hyderabad, enhancing our capacity for sterile injectables. The unit will create over 300 jobs and boost exports to European markets.
Read MoreMay 3, 2023
We announced a strategic partnership with the Global Health Alliance to supply affordable antiretroviral drugs to Sub-Saharan Africa, supporting the fight against HIV/AIDS.
Read MoreApril 20, 2023
Calico launched 'Gluconova', a new DPP-4 inhibitor for type 2 diabetes, offering better glycemic control with minimal side effects. The drug received CDSCO approval and is now available across India.
Read MoreWe welcome inquiries from healthcare professionals, partners, and patients. Reach out to us for product information, collaborations, or support.
We collaborate with leading organizations and recommend these valuable resources.